Therapeutic and nutraceutical potentials of a brown seaweed Sargassum fusiforme

Jian Liu, Sibusiso Luthuli, Yue Yang, Cheng Yang, Ya Zhang, Mingjiang Wu, Jong‐il Choi, Haibin TongFood 2020 · DOI

TL;DR

This review synthesizes current research on Sargassum fusiforme, a brown seaweed with a long history of medicinal and culinary use. It highlights the seaweed's diverse therapeutic and nutraceutical potential, including anticancer, antiangiogenic, antioxidant, and immunomodulatory effects, suggesting it's a promising source for novel functional ingredients and pharmaceuticals.

What Problem Does This Paper Address?

Despite its traditional use and growing popularity, there's a relative lack of comprehensive scientific research on the specific therapeutic and nutraceutical benefits of Sargassum fusiforme. This paper aims to address this gap by reviewing existing studies, primarily from the past two decades, to consolidate our understanding of its potential applications. The authors highlight the need for further research to fully explore and validate these benefits, paving the way for its broader utilization in health and wellness.

Methods

This paper is a review article, meaning it does not present new experimental data or methodologies. Instead, it synthesizes and analyzes existing research published in scientific literature. The authors have systematically gathered and discussed findings from various in vitro and in vivo studies that investigate the therapeutic effects of Sargassum fusiforme and its derived compounds, particularly polysaccharides. The review categorizes these effects into distinct areas such as apoptosis induction, antiangiogenesis, UV protection, antioxidant activity, neuroprotection, and immunomodulation.

Datasets

Not discussed in the paper. This is a review article that synthesizes existing research and does not introduce or utilize specific datasets for training or evaluation.

Key Insights and Ideas

  • Rich Bioactive Profile: Sargassum fusiforme is a treasure trove of bioactive compounds, with polysaccharides (especially fucoidans) being a major focus due to their diverse health-promoting properties.
  • Multifaceted Therapeutic Potential: Beyond general health benefits, the seaweed demonstrates specific therapeutic actions, including:
  • Anticancer: Inducing apoptosis in cancer cells and inhibiting tumor growth and angiogenesis.
  • Antiangiogenic: Suppressing the formation of new blood vessels that tumors rely on.
  • Antioxidant: Scavenging free radicals and protecting against oxidative stress, potentially slowing aging.
  • Neuroprotective: Showing promise in treating neurodegenerative disorders.
  • Immunomodulatory: Enhancing immune responses and potentially mitigating chemotherapy side effects.
  • UV Protection: Offering defense against UV-B radiation damage to the skin.
  • Gut Health: Modulating gut microbiota and promoting intestinal homeostasis.
  • Structural-Activity Relationship is Key: While many bioactivities are observed, the precise relationship between the chemical structure of Sargassum fusiforme polysaccharides and their specific biological effects remains an area requiring deeper investigation.
  • Sustainable Resource: As a readily available marine resource, Sargassum fusiforme presents an opportunity for sustainable development of functional foods, nutraceuticals, and pharmaceuticals.

Key Results

The review consolidates findings from numerous studies, indicating that Sargassum fusiforme extracts and isolated polysaccharides exhibit significant bioactivities:

  • Anticancer: Studies show SFPSs (Sargassum fusiforme polysaccharides) can induce apoptosis in liver and gastric cancer cells and inhibit tumor growth and angiogenesis in lung cancer models. For example, FP08S2, a sulfated fucoidan fraction, inhibited VEGF-A and VEGFR2 expression, crucial for angiogenesis.
  • Antioxidant: SFPSs have demonstrated strong in vitro and in vivo antioxidant activity, upregulating Nrf2-dependent cytoprotection and potentially decelerating aging.
  • UV Protection: An in vivo study showed SFPSs protected against UV-B radiation damage in mice, reducing oxidative stress and inflammatory markers.
  • Neuroprotection: Fucosterol from S. fusiforme showed anticonvulsant and antidepressant effects, while a fucoidan (SFPS65A) improved cognitive function in mice.
  • Antibacterial: Extracts of S. fusiforme have shown inhibitory effects against multidrug-resistant bacteria.
  • Antiviral: Extracts have demonstrated inhibition of HIV replication.
  • Immunomodulatory: SFPSs have shown immune-enhancing effects, promoting splenic lymphocyte proliferation and cytokine production.

Limitations and Future Work

The authors acknowledge several limitations and suggest future research directions:

  • Structure-Function Relationship: A significant limitation is the unclear relationship between the structural features of Sargassum fusiforme polysaccharides and their bioactivity. Future studies should systematically examine these structure-function relationships.
  • Clinical Translation: While preclinical and in vitro studies show promise, clinical applications remain limited. More human studies are needed to validate these findings and establish efficacy and safety.
  • Causation vs. Correlation: Many studies establish correlations between SFPSs and health benefits. Future research should move towards establishing causal links.
  • Gut Microbiota Interactions: The impact of SFPSs on gut microbiota is an emerging area of interest, and further investigation into these complex interactions is warranted.
  • Extraction and Processing: The influence of different extraction techniques on the properties and bioactivity of fucoidans needs further exploration.
  • Drug Development: The review suggests that Sargassum fusiforme compounds could be valuable for developing novel therapies, particularly for cancer, neurodegenerative disorders, and infectious diseases. Continued research into isolation, characterization, and formulation of these compounds is crucial.

Summary updated

Abstract

<i>Sargassum fusiforme</i>, also known as Yangqicai () in Chinese and <i>Hijiki</i> in Japanese, is a brown seaweed that grows abundantly along the rocky coastlines of Asian countries such as Japan, Korea, and China. The first use of <i>S. fusiforme</i> as a traditional Chinese medicinal plant was recorded in the Shennong Bencao Jing, dated 200 AD. It was referred to as Haizao (seaweed), renowned for treating Yinglu (tumor-like induration), dysuria, and edema. Currently, it is commonly used in traditional cuisine as it is rich in dietary fiber and minerals such as calcium, iron, and magnesium. Owing to its health benefits, <i>S. fusiforme</i> remains popular in China, Korea, and Japan, as well as in the UK and in North America. Currently, there is a lack of research on <i>S. fusiforme</i>; thus, we review the therapeutic effects of <i>S. fusiforme</i>, such as anticancer, antiangiogenic, and antiviral effects, in vitro and in vivo as reported during the past two decades. This review may promote further research on the therapeutic uses of <i>S. fusiforme</i>. Furthermore, we discuss the processes and considerations involved in using drugs produced from marine sources.
BibTeX
@inproceedings{liu2020therapeutic,
  author = {Jian Liu and Sibusiso Luthuli and Yue Yang and Cheng Yang and Ya Zhang and Mingjiang Wu and Jong‐il Choi and Haibin Tong},
  title = {{Therapeutic and nutraceutical potentials of a brown seaweed <i>Sargassum fusiforme</i>}},
  booktitle = {Food},
  year = {2020},
  doi = {10.1002/fsn3.1835},
}
Figure